A Systematic Review on the Quality, Validity and Usefulness of Current Cost-Effectiveness Studies for Treatments of Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica - United States
doi 10.1111/aos.13824
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Cost-Effectiveness of Intravitreal Aflibercept Injection (IAI) in Treating Neovascular Age-Related Macular Degeneration in the US

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Age-Related Macular Degeneration—Review and Current Concepts

US Ophthalmic Review
2011English

Development and Testing of a Patient-Derived Questionnaire for Treatment of Neovascular Age-Related Macular Degeneration: Dimensions of Importance in Treatment of Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Treatment of Age-Related Neovascular Macular Degeneration: The Patient’s Perspective

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration

Ophthalmology
Ophthalmology
2014English

Appraising the Quality of Systematic Reviews for Age-Related Macular Degeneration Interventions

JAMA Ophthalmology
Ophthalmology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy